Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors? Article uri icon

Overview

abstract

  • Tumors that elude infiltration by CD8+ T lymphocytes are particularly resistant to multiple forms of treatment, including immune checkpoint blockade. Stromal transforming growth factor (TGF)-β appears to play a key role in this process, potentially constituting a target for novel combinatorial regimens tackling immune-excluded neoplasms.

publication date

  • March 26, 2018

Research

keywords

  • Immune Evasion
  • Transforming Growth Factor beta

Identity

PubMed Central ID

  • PMC5972064

Scopus Document Identifier

  • 85044266372

Digital Object Identifier (DOI)

  • 10.1016/j.it.2018.03.002

PubMed ID

  • 29598848

Additional Document Info

volume

  • 39

issue

  • 6